Compound Methyl Salicylate Liniment

PreclinicalSmall molecule

Compound Methyl Salicylate Liniment is one of 2 small molecule programs targeting Clinical Efficacy and Safety. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical Efficacy and SafetyCompleted

Clinical Efficacy and SafetyPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Clinical Efficacy and Safety

#DrugCompanyPhaseTrials

Analgesic

CCeren Melahat Donmezer

Preclinical

1 2

Compound Methyl Salicylate Liniment

PPeking University People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Efficacy and Safety1 trial

Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment

Completed·PPeking University People's Hospital·N/A·NCT03362216·216 enrolled

Clinical Trial1 trial

Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL

Unknown status·PPeking University People's Hospital·Phase 3·NCT04175587·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Compound Methyl Salicylate Liniment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Compound Methyl Salicylate Liniment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Compound Methyl Salicylate Liniment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University People's Hospital

Compound Methyl Salicylate Liniment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Efficacy and Safety1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News